Evidence map›Paper›PMID 35949908›Full record

ArticleCase reports in oncology

Efficacy of Decitabine and Venetoclax as Salvage and Bridge Therapy to Haploidentical Hematopoietic Stem Cell Transplantation in a Multiresistant Acute Myeloid Leukemia Patient.

Bianca Serio, Valentina Giudice, Denise Morini, Roberto Guariglia, Rosa Vitolo, Paola Manzo, Maddalena Langella, Carmine Selleri

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Bianca SerioHematology and Transplant Center, University Hospital "San Giovanni di Dio e Ruggi d'Aragona,", Salerno, Italy.
Valentina GiudiceHematology and Transplant Center, University Hospital "San Giovanni di Dio e Ruggi d'Aragona,", Salerno, Italy.
Denise MoriniHematology and Transplant Center, University Hospital "San Giovanni di Dio e Ruggi d'Aragona,", Salerno, Italy.
Roberto GuarigliaHematology and Transplant Center, University Hospital "San Giovanni di Dio e Ruggi d'Aragona,", Salerno, Italy.
Rosa VitoloHematology and Transplant Center, University Hospital "San Giovanni di Dio e Ruggi d'Aragona,", Salerno, Italy.
Paola ManzoHematology and Transplant Center, University Hospital "San Giovanni di Dio e Ruggi d'Aragona,", Salerno, Italy.
Maddalena LangellaHematology and Transplant Center, University Hospital "San Giovanni di Dio e Ruggi d'Aragona,", Salerno, Italy.
Carmine SelleriHematology and Transplant Center, University Hospital "San Giovanni di Dio e Ruggi d'Aragona,", Salerno, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Treatment of relapsed/refractory or elderly unfit acute myeloid leukemia (AML) is still challenging, and hypomethylating agents in combination with venetoclax, an oral selective BCL2 inhibitor, might be successfully used as salvage therapy. However, clinical trials evaluating the efficacy and safety of this combination in the setting of multiresistant AML treatment also as a bridge to transplant are still ongoing. Here, we reported a 50-year-old male diagnosed with AML with normal cytogenetics and wild type for fms-like tyrosine kinase 3, nucleophosmin 1, and KIT, and treated with decitabine and venetoclax as the fifth line of therapy and after a relapse post-allogeneic transplant. The patient achieved a complete remission and successfully underwent a haploidentical transplant with an overall survival of 48.6 months.

Indexed as

Acute myeloid leukemiaBCL2 inhibitorHematopoietic stem cell transplantationHypomethylating agentsSalvage therapy

Identifiers

PMID35949908
PMCPMC9247557

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.